Compare JCSE & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JCSE | SILO |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | Singapore | United States |
| Employees | N/A | 3 |
| Industry | Miscellaneous manufacturing industries | Apparel |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 379.7K |
| IPO Year | 2022 | 2011 |
| Metric | JCSE | SILO |
|---|---|---|
| Price | $1.33 | $6.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.5K | ★ 284.4K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.18% | N/A |
| EPS Growth | N/A | ★ 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.22 |
| 52 Week High | $2.50 | $1.01 |
| Indicator | JCSE | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 97.03 |
| Support Level | $1.02 | $0.38 |
| Resistance Level | $1.46 | N/A |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | 0.01 | 0.35 |
| Stochastic Oscillator | 60.00 | 96.10 |
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company has two operating segments namely sale of cleaning systems and other equipment and provision of centralized dishware washing and general cleaning services. Geographically, the company derives a majority of its revenue from Singapore.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.